DOGWOOD THERAPEUTICS INC

Dogwood Therapeutics (DWTX) trades near its 52‑week low after a new $1.22 private placement—consider buying at $0.80–$1.00 to capitalize on potential pipeline upside while weighing dilution risks.

Dogwood Therapeutics (DWTX) drops 4.96% as investors weigh a new antiviral pipeline, cost cuts, and upcoming FDA milestones that could spark a rally.